Cancer Statistics, 2009
2009/05/27 by Ahmedin Jemal, A. Jemal, R. Siegel +8 · 38 citations
Medicine · #Global Cancer Incidence and Screening #Colorectal Cancer Screening and Detection #Cancer Risks and Factors
paper · doi:10.3322/caac.20006
Abstract
Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. Incidence and death rates are standardized by age to the 2000 United States standard million population. A total of 1,479,350 new cancer cases and 562,340 deaths from cancer are projected to occur in the United States in 2009. Overall cancer incidence rates decreased in the most recent time period in both men (1.8% per year from 2001 to 2005) and women (0.6% per year from 1998 to 2005), largely because of decreases in the three major cancer sites in men (lung, prostate, and colon and rectum [colorectum]) and in two major cancer sites in women (breast and colorectum). Overall cancer death rates decreased in men by 19.2% between 1990 and 2005, with decreases in lung (37%), prostate (24%), and colorectal (17%) cancer rates accounting for nearly 80% of the total decrease. Among women, overall cancer death rates between 1991 and 2005 decreased by 11.4%, with decreases in breast (37%) and colorectal (24%) cancer rates accounting for 60% of the total decrease. The reduction in the overall cancer death rates has resulted in the avoidance of about 650,000 deaths from cancer over the 15-year period. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, education, geographic area, and calendar year. Although progress has been made in reducing incidence and mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons younger than 85 years of age. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population and by supporting new discoveries in cancer prevention, early detection, and treatment.
Cited by
- Prevention of Barrett Esophagus and Esophageal Adenocarcinoma by Smoothened Inhibitor in a Rat Model of Gastroesophageal Reflux Disease
- Socioeconomic and lifestyle factors and melanoma: a systematic review
- β-Lapachone Micellar Nanotherapeutics for Non–Small Cell Lung Cancer Therapy
- OR Forum—A POMDP Approach to Personalize Mammography Screening Decisions
- Pathways of metastasis suppression in bladder cancer
- Does Google Scholar contain all highly cited documents (1950-2013)?
- Hypoxia, inflammation, and the tumor microenvironment in metastatic disease
- <i>In Vitro</i> and <i>In Vivo</i> Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
- Papillary thyroid carcinoma: an update
- Molecular docking and dynamics simulations of bioactive terpenes from <i>Catharanthus roseus</i> essential oil targeting breast cancer
- Core fucosylation and 2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia
- Apoptotic effect of eugenol in human colon cancer cell lines
- Interventions to promote colorectal cancer screening: An integrative review
- Premature menopause or early menopause: long-term health consequences. [europepmc]
- Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. [europepmc]
- Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. [europepmc]
- Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. [europepmc]
- The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. [europepmc]
- Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. [europepmc]
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. [europepmc]
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. [europepmc]
- Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. [europepmc]
- Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. [europepmc]
- Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. [europepmc]
- Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. [europepmc]
- The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. [europepmc]
- Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. [europepmc]
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. [europepmc]
- Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. [europepmc]
- Targeted therapies for hepatocellular carcinoma. [europepmc]
- Integrated genomic analyses of ovarian carcinoma. [europepmc]
- Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. [europepmc]
- CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. [europepmc]
- ESUR prostate MR guidelines 2012. [europepmc]
- Identification of Lynch syndrome among patients with colorectal cancer. [europepmc]
- BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. [europepmc]
- Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. [europepmc]
- Pancreatic cancer: A review of epidemiology, trend, and risk factors. [europepmc]
Related